(NASDAQ: LPTX) Leap Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Leap Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast LPTX's revenue for 2025 to be $3,960,372,024, with the lowest LPTX revenue forecast at $3,960,372,024, and the highest LPTX revenue forecast at $3,960,372,024. On average, 1 Wall Street analysts forecast LPTX's revenue for 2026 to be $229,586,784, with the lowest LPTX revenue forecast at $229,586,784, and the highest LPTX revenue forecast at $229,586,784.
In 2027, LPTX is forecast to generate $2,558,170,741 in revenue, with the lowest revenue forecast at $1,104,695,076 and the highest revenue forecast at $4,011,646,406.